We are live on ! Find out more
KCM

Kennondale Capital Management Portfolio holdings

AUM $139M
1-Year Est. Return 44.52%
This Fund
S&P 500
This Quarter Est. Return
+10.6%
1 Year Est. Return
+44.52%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$98M
AUM Growth
+$6.27M
Cap. Flow
+$221K
Cap. Flow %
0.23%
Top 10 Hldgs %
30.47%
Holding
83
New
2
Increased
1
Reduced
4
Closed
1

Top Buys

Rank Stock Value
1
AMR icon
Alpha Metallurgical Resources
AMR
+$780K
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$555K
3
STOK icon
Stoke Therapeutics
STOK
+$181K

Top Sells

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$523K
2
PRDO icon
Perdoceo Education
PRDO
+$323K
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$244K
4
PCH
PotlatchDeltic
PCH
+$206K
5
IBKR icon
Interactive Brokers
IBKR
+$47

Sector Composition

Rank Sector Weight
1 Financials 25.99%
2 Industrials 15.9%
3 Energy 11.82%
4 Consumer Discretionary 9.18%
5 Healthcare 8.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
51
DELISTED
Akero Therapeutics
AKRO
$753K 0.77%
14,108
– –
AMR icon
52
Alpha Metallurgical Resources
AMR
$1.93B
$751K 0.77%
+6,676
New +$780K
VRTS icon
53
Virtus Investment Partners
VRTS
$1.1B
$745K 0.76%
4,107
– –
IDCC icon
54
InterDigital
IDCC
$8.89B
$745K 0.76%
3,321
– –
BDC icon
55
Belden
BDC
$5.19B
$735K 0.75%
6,345
– –
HUM icon
56
Humana
HUM
$46.2B
$727K 0.74%
2,972
– –
FCN icon
57
FTI Consulting
FCN
$4.18B
$708K 0.72%
4,383
– –
ACA icon
58
Arcosa
ACA
$7.11B
$703K 0.72%
8,103
– –
PINC
59
DELISTED
Premier
PINC
$698K 0.71%
31,822
– –
STOK icon
60
Stoke Therapeutics
STOK
$2.11B
$694K 0.71%
61,183
+19,083
+45% +$181K
SENEA icon
61
Seneca Foods Class A
SENEA
$1.21B
$682K 0.7%
6,721
– –
AMLX icon
62
Amylyx Pharmaceuticals
AMLX
$2.54B
$610K 0.62%
95,165
-107,578
-53% -$523K
PLXS icon
63
Plexus
PLXS
$7.23B
$596K 0.61%
4,404
– –
FR icon
64
First Industrial Realty Trust
FR
$8.44B
$576K 0.59%
11,963
– –
LPX icon
65
Louisiana-Pacific
LPX
$5.49B
$542K 0.55%
6,306
– –
FULT icon
66
Fulton Financial
FULT
$4.64B
$522K 0.53%
28,942
– –
FRME icon
67
First Merchants
FRME
$2.67B
$517K 0.53%
13,495
– –
PRK icon
68
Park National Corp
PRK
$3.67B
$481K 0.49%
2,878
– –
BUD icon
69
AB InBev
BUD
$165B
$457K 0.47%
6,643
– –
FANG icon
70
Diamondback Energy
FANG
$52.7B
$448K 0.46%
3,260
– –
CNC icon
71
Centene
CNC
$32.5B
$443K 0.45%
8,163
– –
WY icon
72
Weyerhaeuser
WY
$18.4B
$441K 0.45%
17,177
– –
AWR icon
73
American States Water
AWR
$3.46B
$425K 0.43%
5,540
– –
ZIM icon
74
ZIM Integrated Shipping Services
ZIM
$3.24B
$401K 0.41%
24,916
– –
IOVA icon
75
Iovance Biotherapeutics
IOVA
$2.87B
$384K 0.39%
+223,054
New +$555K
1 2
3
4

Similar funds

PAM
Parvin Asset Management Sioux Falls, South Dakota $139M AUM 49.07% 1-Year Est. Return
BCP
Bluegrass Capital Partners Palm Beach, Florida $139M AUM 4.03% 1-Year Est. Return
MFF
Michels Family Financial Fort Worth, Texas $139M AUM 20.03% 1-Year Est. Return
CFWMA
Center for Wealth Management Advisory Milford, Ohio $139M AUM
SMA
Seven Mile Advisory Ewing, New Jersey $139M AUM 26.01% 1-Year Est. Return
BCA
Buckley Capital Advisors Miami Beach, Florida $139M AUM
CI
Chartist Inc Seal Beach, California $139M AUM
LIP
Landmark Investment Partners West Palm Beach, Florida $139M AUM 16.97% 1-Year Est. Return

Kennondale Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Kennondale Capital Management held 83 positions worth $98M, up 6.8% from $91.7M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 3.6%. Kennondale Capital Management opened 2 new positions and exited 1, leaving the 83-position portfolio largely intact.

By sector, the portfolio is most concentrated in Financials at 26% of assets, up from 25% a quarter earlier, followed by Industrials and Energy.

  • Kennondale Capital Management's largest Q2 2025 buy was Alpha Metallurgical Resources: 6,676 shares worth $751K.
  • Kennondale Capital Management added most to Stoke Therapeutics in Q2 2025, an estimated $181K increase.
  • Kennondale Capital Management's biggest Q2 2025 reduction was Amylyx Pharmaceuticals, cutting an estimated $523K.
  • Kennondale Capital Management fully exited PotlatchDeltic in Q2 2025, selling an estimated $206K.
  • Kennondale Capital Management's ten largest holdings make up 30% of its $98M portfolio in Q2 2025.
  • Kennondale Capital Management opened 2 new positions and closed 1 in Q2 2025.
  • Kennondale Capital Management's portfolio value rose 6.8% quarter-over-quarter to $98M.

Based on Kennondale Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.